Direct and indirect effects of 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in children hospitalised with pneumonia from formal and informal settlements in Mongolia: an observational study. by Chan, J et al.
The Lancet Regional Health - Western Pacific 15 (2021) 100231 
Contents lists available at ScienceDirect 
The Lancet Regional Health - Western Pacific 
journal homepage: www.elsevier.com/locate/lanwpc 
Research paper 
Direct and indirect effects of 13-valent pneumococcal conjugate 
vaccine on pneumococcal carriage in children hospitalised with 
pneumonia from formal and informal settlements in Mongolia: an 
observational study ✩ 
Jocelyn Chan 1 , 2 , ∗, Tuya Mungun 1 , 3 , Purevsuren Batsaixan 1 , 3 , Mukhchuluun Ulziibayar 1 , 3 , 
Bujinlkham Suuri 1 , 3 , Dashpagam Otgonbayar 3 , Dashtseren Luvsantseren 1 , 3 , 
Cattram D Nguyen 1 , 2 , Dorj Narangarel 3 , Eileen M Dunne 1 , Kimberley Fox 4 , Jason Hinds 5 , 6 , 
Monica L Nation 1 , Casey L Pell 1 , E Kim Mulholland 1 , 2 , 7 , Catherine Satzke 1 , 8 , Claire von 
Mollendorf 1 , 2 , Fiona M Russell 1 , 2 , on behalf of the PneuCAPTIVE Mongolia Research Group 
1 Infection and Immunity, Murdoch Children’s Research Institute (MCRI), Melbourne, Australia 
2 Department of Paediatrics, University of Melbourne, Melbourne, Australia. 
3 National Centre for Communicable Diseases (NCCD), Ministry of Health, Ulaanbaatar, Mongolia. 
4 Regional Office for the Western Pacific, World Health Organization, Manila, Philippines. 
5 Institute for Infection and Immunity, St George’s University of London, London, United Kingdom. 
6 BUGS Bioscience, London Bioscience Innovation Centre, London, United Kingdom. 
7 Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom. 
8 Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia. 
a r t i c l e i n f o 
Article history: 
Received 31 March 2021 
Revised 7 July 2021 
Accepted 12 July 2021 
Keywords: 







a b s t r a c t 
Background: Within Ulaanbaatar, Mongolia, risk factors for pneumonia are concentrated among children 
living in informal settlements comprised of temporary shelters (gers). We used pneumococcal carriage 
surveillance among children from formal and informal settlements hospitalised with pneumonia to eval- 
uate the direct and indirect effects of 13-valent pneumococcal conjugate vaccine (PCV13) against vaccine- 
type (VT) pneumococcal carriage following a phased introduction of PCV13. 
Methods: We enrolled and collected nasopharyngeal swabs from children 2-59 months of age presenting 
to hospital. Pneumococci were detected using lytA qPCR and serotyped using microarray on a random 
monthly selection of swabs between November 2015 and March 2019 from two districts in Ulaanbaatar. 
PCV13 status was determined using written records. We quantified the associations between individual 
PCV13 status (direct effects) and district-level PCV13 coverage (indirect effects) and VT carriage using 
generalised estimating equations and explored interactions by settlement type. 
Findings: A total of 1 292 swabs from 6 046 participants were tested for pneumococci. Receipt of 
PCV13 and increasing PCV13 coverage independently reduced the risk of VT carriage. For each percent 
increase in PCV13 coverage, the adjusted odds of VT carriage decreased by 1 • 0% (OR 95% CI 0 • 983-0 • 996; 
p = 0 • 001), with a predicted decrease in VT carriage rate from 29 • 1% to 13 • 1% as coverage reached 100%. 
There was a trend towards a slower decline within informal settlements (p = 0 • 100). Adjusted PCV13 vac- 
cine effectiveness against VT carriage was 39 • 1% (95% CI 11 • 4-58 • 1%, p = 0 • 009). 
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Research in context 
Evidence before this study 
We searched PubMed for studies evaluating the relation- 
ship between pneumococcal conjugate vaccine (PCV) cover- 
age and indirect effects published between January 2001 and 
January 2021. We used the terms “pneumococcal conjugate 
vaccine”, “indirect”, “herd” and “vaccine coverage”. We fur- 
ther supplemented the search with expert input from co- 
authors to identify any relevant studies. We identified a total 
of five studies examining the association between PCV cover- 
age and indirect effects on either disease (n = 3) or vaccine- 
type (VT) carriage (n = 2). All studies describe an associa- 
tion between PCV coverage and pneumococcal disease or VT 
carriage. Only one of these research studies was conducted 
in either a low- or middle-income country – Brazil. This 
study found that higher uptake of PCV10 within a mesore- 
gion was associated with fewer pneumonia hospitalisations 
among children aged less than 12 months (marginal mean 
rate ratio [RR] 0 • 83; 95% CI 0 • 72-0 • 96) and among adults 
aged 18–39 years (marginal mean RR 0 • 81; 95% CI 0 • 70-0 • 93). 
One of the studies was a meta-analysis of 70 studies, includ- 
ing seven middle-income countries. This meta-analysis found 
greater reductions in disease due to PCV7 serotypes in set- 
tings with higher PCV coverage (per percentage; RR 0 • 995, 
95% credible interval 0 • 989-0 • 998). None of the studies ad- 
justed for individual-level confounders. 
The two studies from the United States indicated that 
moderate levels of PCV coverage were sufficient for substan- 
tial indirect effects. However, both studies were ecological 
in study design. In contrast, carriage surveys from Malawi, 
which did not specifically examine the relationship between 
PCV coverage and VT carriage, showed high levels of circulat- 
ing VT carriage despite high levels of vaccine coverage seven 
years post-PCV introduction, indicating that further research 
using more robust study designs is required in a range of set- 
tings. 
Added value of this study 
Our research addresses a critical gap in our understand- 
ing of the relationship between PCV coverage and indirect ef- 
fects. Our findings show that in Mongolia, which introduced 
13-valent PCV (PCV13) and included a catch-up campaign for 
children up to two years of age, indirect effects were ob- 
served at low levels of PCV13 coverage and increased as vac- 
cine coverage increased. 
Our results also help to explain why control of VTs have 
been challenging in settings with high rate of VT carriage, de- 
spite high rates of vaccine coverage. While we observed indi- 
rect effects in children across both formal and informal set- 
tlements in Mongolia, the association between PCV coverage 
and indirect effects differed by settlement type. There was a 
trend towards greater indirect effects at lower levels of cov- 
erage for children living in apartment subdistricts (formal), 
compared with children living in ger subdistricts (informal) 
and mixed subdistricts, who have a higher rate of VT car- 
riage. Hence, our results support dynamic modelling studies 
demonstrating that higher rates of vaccine coverage are re- 
quired to effectively interrupt person-to-person transmission 
in populations with high prevalence and transmission of VTs. 
Implications of all the available evidence d
2 ect effects were observed following PCV13 introduction, including among
settlements. 
Foundation; Gavi, the Vaccine Alliance. 
© 2021 The Authors. Published by Elsevier Ltd. 
icle under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
Our results demonstrate indirect effects following PCV13 
introduction in Mongolia, supporting the inclusion of indi- 
rect effects in a previous economic model in Mongolia which 
found PCV to be highly cost-effective, reducing disease costs 
by US$440 0 0 0 in the first year of PCV introduction. These re- 
sults have relevance for other countries in the region, many 
of which have not yet introduced PCV. 
Globally, there is strong interest in reducing the number 
of PCV doses (from three or four doses to two doses) to min- 
imise program costs once VTs have been controlled. However, 
reduced-dose schedules rely on sufficient indirect effects to 
maintain vaccine impacts. Not all countries have surveillance 
systems capable of accurately measuring indirect effects on 
disease. This study demonstrates how pneumococcal carriage 
surveillance can be used to monitor the control of VTs and 
potentially be applied to monitor the maintenance of indirect 
effects following any schedule change. Our findings also con- 
tribute ne insight into conditions necessary to generate in- 
direct effects – demonstrating that higher PCV coverage may 
be required in settings with high prevalence of VTs. Indeed, 
high vaccination coverage alone may not be sufficient to con- 
trol VTs in settings with very high prevalence of VT pneumo- 
cocci. Alternative schedules, or wider catch-up programs en- 
compassing children over five years of age may be required 
to achieve control of VTs. Further research is needed to un- 
derstand social and environmental conditions contributing to 
high prevalence of VT pneumococci and to develop suitable 
vaccination strategies for these settings. 
. Introduction 
Pneumococcal disease, including meningitis, septicaemia and 
neumonia, is a leading cause of child morbidity and mortality 
lobally, and the burden is not evenly distributed across or within 
ountries. 1 Pneumococcal disease is preceded by nasopharyngeal 
neumococcal carriage, and transmission of pneumococci occurs 
hrough close contact with carriers. 2 Risk factors such as mal- 
utrition, air pollution and overcrowding concentrate the disease 
mong the most marginalised children within societies. 3 , 4 Pneu- 
ococcal conjugate vaccines (PCVs) have substantially reduced a 
arge global burden of disease due to Streptococcus pneumoniae in 
any settings. 1 The vaccine provides both direct effects to vacci- 
ated children and indirect effects to the wider population. 5 Re- 
ucing the number of people who are susceptible to vaccine-type 
VT) pneumococcal carriage through vaccination results in reduced 
f transmission VT pneumococci – protecting both vaccinated and 
nvaccinated individuals in that population. 6 These are known as 
he indirect or herd effects of a vaccine. 
Indirect effects extend the benefits of the vaccine to unvacci- 
ated groups, including infants too young to be vaccinated and the 
lderly. 5 Furthermore, indirect effects are critical to achieve con- 
rol of VTs – a prerequisite for the introduction of reduced dose 
chedules. Reduced dose schedules aim to maintain vaccine impact 
hile reducing PCV program costs through the use of only two 
oses (as opposed to three or four doses). 7 In particular, reduced- 
ose schedules rely on the continued generation of indirect effects 





















































































































o protect infants who have not received sufficient doses to gener- 
te individual protection, but are highly susceptible to disease. 7 
Respiratory diseases, including pneumonia, are the second 
argest cause of under-five mortality in Mongolia. 8 Prior to PCV 
ntroduction, there was a high incidence of all-cause pneumonia 
ospitalisations among children 12-59 months of age, at an esti- 
ated 31 • 8 per 1 0 0 0 population 9 High levels of air pollution and
xtremes of cold temperature in winters contribute to a season- 
lly high burden of pneumonia. 10 While local data on the aetiology 
f childhood pneumonia is limited, modelled estimates of pneu- 
ococcal pneumonia incidence (19 • 8 per 1 0 0 0 population [95% 
redible interval 17 • 1-23 • 6]) suggest that the pneumococcus is re- 
ponsible for a large proportion of the overall pneumonia burden 
n Mongolia. 1 
Forty-five percent of the Mongolian population resides in the 
apital city of Ulaanbaatar. 11 Rapid urbanisation has led to the 
rowth of informal settlements comprising of ger dwellings (tradi- 
ional temporary shelters) clustered in particular subdistricts (ger 
ubdistricts). Within ger subdistricts, there are issues of household 
rowding and air pollution (from burning coal for heating), which 
re risk factors for pneumonia and pneumococcal disease. 3 , 12–14 
rom the latest census, 30.4% of the city’s population live in gers. 
hese health and socioeconomic inequalities are characteristic of 
any urban settings in the Asia-Pacific region. 15 There is no evi- 
ence on the impact of PCVs within informal settlements. 
Mongolia was among the first countries in Asia to introduce 
CV. 16 The phased introduction of 13-valent PCV (PCV13) com- 
enced in 2016 and is being evaluated through enhanced pneu- 
onia surveillance. 17 Monitoring the indirect effects of PCVs can 
e challenging. 18 The recommended method for evaluating PCV 
mpact – invasive pneumococcal disease (IPD) surveillance – re- 
uires large number of samples to detect a rare outcome (IPD). 19 
lternatively, surveillance of pneumococcal carriage can be eas- 
er to establish and is well-suited to monitoring indirect effects, 
ince indirect effects are mediated by reductions in VT carriage. 18 
ommunity carriage surveys conducted before and one year after 
CV13 introduction found a 51% reduction in VT carriage (adjusted 
revalence ratio 0.49 [95% CI 0.33–0.73]) in unvaccinated infants 
ged 5-8 weeks, indicating the presence of indirect effects. 20 
Indirect effects are traditionally measured by comparing the in- 
idence of disease among unvaccinated individuals before and after 
accine introduction, since unvaccinated individuals are reliant on 
ndirect effects for protection. However, in this study we adapted 
 method pioneered by Ali et al, which evaluates indirect effects 
y assessing correlations between levels of vaccine coverage and 
accine-related outcomes (VT carriage) among both vaccinated and 
nder-vaccinated individuals, since both groups benefit from in- 
irect effects. 21 Conducting ongoing carriage surveillance among 
hildren hospitalised with pneumonia allowed us to characterise 
radual changes in carriage patterns and explore the relationship 
etween PCV13 coverage and vaccine impact. Furthermore, car- 
iage surveillance among this cohort is more likely to represent the 
erotypes responsible for disease, compared to studies conducted 
mong healthy children in the community. 
In Mongolia, we hypothesise that VT carriage will decline post- 
CV13 introduction and that the risk of VT carriage declines both 
s district-level PCV13 coverage rises and by individual PCV13 vac- 
ination status. Using carriage surveillance among children hos- 
italised with pneumonia in Ulaanbaatar, we aim to: 1) describe 
rends in VT carriage pre- and post-PCV13 introduction, 2) describe 
he relationship between district-level PCV13 coverage and risk of 
T carriage (i.e., indirect effects), and 3) calculate the PCV13 vac- 
ine effectiveness (VE) (i.e., direct effects) against VT carriage. As 
art of Aim 2, we also explore an interaction between PCV13 cov- 
rage and subdistrict type (apartment, ger or mixed housing). a
3 . Methods 
.1. Study setting 
Ulaanbaatar has a population of approximately 1 • 3 million peo- 
le, divided into nine districts and 121 subdistricts. 11 This study 
as conducted among children resident in two districts (Songi- 
okhairkhan and Sukhbaatar) in Ulaanbaatar – the first to receive 
CV13 as part of a phased introduction in June 2016. PCV13 was 
ntroduced in one additional district (Bayanzurkh) one year later 
nd rolled out across the rest of Ulaanbaatar in March 2018. Chil- 
ren received a “2 + 1” schedule given at two, four and nine months 
f age. A three-month catch-up campaign, comprised of two doses 
or children 3-23 months of age, accompanied vaccine introduc- 
ion in the first three districts. 17 Immunisations are available at no 
ost through family health centres to which children are registered 
ased on their subdistrict of residence. PCV coverage among the 
arget age group within the PCV intervention districts was reported 
o be 97-98% from 2017-2019. 22 Mongolia does not have an adult 
neumococcal vaccination program. 
.2. Study design, participant recruitment and data collection 
This observational study was embedded within an enhanced 
ospital-based pneumonia surveillance system which commenced 
n April 2015, modified from the World Health Organization Inva- 
ive Bacterial Vaccine Preventable Disease (WHO IB-VPD) Surveil- 
ance, and conducted in partnership between the Murdoch Chil- 
ren’s Research Institute (MCRI), the WHO and the Mongolian Min- 
stry of Health. 
Participants with pneumonia were recruited from four partici- 
ating district hospitals and the tertiary Maternal and Child Health 
ospital according to a previously published protocol. 17 These hos- 
itals represent the entirety of public hospital care for the two 
tudy districts. Most pneumonia cases are likely to be captured by 
he public hospital system, since the vast majority of healthcare 
or children is provided by the public sector, with few children 
ccessing private care. The two study districts, Songinokhairkhan 
nd Sukhbaatar, comprise approximately 36% of the city’s popu- 
ation and are broadly representative of Ulaanbaatar. 11 , 17 In brief, 
ospital staff members identify admissions that meet the eligibil- 
ty criteria, complete a standard case report form (CRF) and col- 
ect relevant specimens. Participants were eligible if they resided 
ithin the two study districts included in the initial phased PCV13 
ntroduction, were aged 2-59 months, and presented with cough or 
ifficulty breathing, and either a respiratory rate ≥ 50 breaths per 
inute, hypoxia (oxygen saturation < 90%) or a clinical diagnosis 
f severe pneumonia. 17 
We collected information on demographics, clinical presenta- 
ion, dates of PCV administration, antibiotics received and risk 
actors for pneumococcal carriage (see Supplementary Table 3). 
CV13 status was determined using written records from parent- 
eld child health cards and validated against an electronic immu- 
isation register. 23 PCV13 vaccination status was based on docu- 
ented PCV13 doses at least 14 days before enrolment. Partici- 
ants were defined as ‘vaccinated’ if they received an adequate 
umber of doses for immune protection (i.e., two or more PCV13 
oses at < 12 months of age or at least one dose after the age of
2 months). Under-vaccinated participants included those who had 
eceived no doses. 18 We classified each child’s residence into either 
ormal (houses and apartments) or informal (gers) housing. Clas- 
ification of subdistricts based on the predominant housing type 
ere provided by the City Health Department; the categories were 
) apartments, 2) gers or 3) mixed subdistricts (combination of 
partments, houses and gers). 

















































































































From each participant, we collected a single nasopharyngeal 
ample on admission using a paediatric flocked swab. Where pos- 
ible, the sample was obtained prior to antibiotic administration, 
owever antibiotic status at the time of swab collection was col- 
ected as part of the CRF. We stored the sample in 1ml of skim 
ilk tryptone glucose glycerol (STGG) medium then transported 
t to the National Centre for Communicable Disease laboratories 
Ulaanbaatar, Mongolia). 24 We tested for pneumococcal carriage 
mong participants enrolled six months pre-PCV13 introduction 
nd up to two years and 10 months post-PCV13 introduction. 5 To 
chieve our sample size of 1 200 (see sample size section below), a 
andom sample of 33 swabs were selected for testing each month. 
andom samples were selected by sorting on random numbers 
enerated using the runiform function in Stata 15. Similar meth- 
ds were employed as part of a multi-site study to examine the 
elationship between PCV13 coverage and indirect effects. 18 
Participant data were double-entered using electronic 
atabases. Regular double-entry discrepancy and logic checks 
ere conducted prior to analysis. 
.3. District vaccination coverage 
Data on monthly number of PCV13 doses administered within 
ach district were collated by staff from the Mongolian Expanded 
rogramme of Immunizations team (Supplementary Tables 1 and 
). These data were collected from written registration books at 
amily health centres (Supplementary Methods page 1) which doc- 
mented personal identifiers and dates of PCV13 administration. 
opulation data estimates were provided by the Mongolian Depart- 
ent of Health for 2018. Monthly district-level vaccination cover- 
ge was calculated as the number of children who had received 
t least two doses of PCV13 divided by the total number of chil- 
ren under five years within each district. Two doses are consid- 
red sufficient to offer protection for infants and at least one dose 
n children over 12 months of age. 25 , 26 However, date of birth was 
ot available to calculate exact age from the routine administrative 
mmunisation registers so we defined any child under five who had 
eceived two doses of PCV13 to be vaccinated. 
.4. Laboratory methods 
Nasopharyngeal samples were vortexed and dispensed into 
liquots for freezing at ultra-low temperatures ( ≤-70 °C). Samples 
ere shipped on dry ice to the Murdoch Children’s Research In- 
titute (Melbourne, Australia) for sample testing and analysis ac- 
ording to standard methods. 24 Testing was completed following 
n initial freeze-thaw. Laboratory staff screened for the presence 
f pneumococci using quantitative real-time PCR (qPCR) targeting 
he lytA gene. 27 Molecular serotyping was performed using Senti- 
P v1.5 microarray (BUGS Bioscience) as previously described. 28 , 29 
amples that were lytA qPCR positive (Ct value < 35) but not able 
o be serotyped (either culture negative or due to technical difficul- 
ies) were considered pneumococcal positive, serotype unknown. 
or more details see previously published methods. 27 
We defined VT carriage as carriage of any pneumococcal 
erotype included in the PCV13 vaccine; i.e. serotypes 1, 3, 4, 5, 
A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. Samples were considered 
T carriage positive if they contained at least one PCV13 serotype, 
egardless of any other serotypes present in the sample. Overall 
arriage was defined as carriage of any pneumococcal serotype. 
.5. Analyses 
Participant characteristics were presented by vaccination status, 
ubdistrict type and year to identify trends over time as vaccine 
overage increased. Trends in VT carriage over time were graphed 4 mong vaccinated and under-vaccinated participants (Aim 1). We 
alculated moving carriage rates within 5-month rolling intervals 
o smooth random variation due to small monthly participant 
umbers. Rates were adjusted by age group (2-11 months, 12-23 
onths, 24-59 months) since age is a known determinant of pneu- 
ococcal carriage. We used direct adjustment to account for ran- 
om variation in the age of participants recruited each month. 30 
CV13 vaccination coverage in the two study districts was also 
raphed over time. 
Our primary analyses (Aim 2) examined the relationship be- 
ween district-level PCV13 coverage among children under five 
ears of age and risk of VT carriage. We first ascertained for each 
articipant the district-level PCV13 coverage at their district of res- 
dence within the month of their hospital admission. 
Since participants from the same subdistrict are not indepen- 
ent, we used generalised estimating equations (with a binomial 
istribution, a logit link function, and an exchangeable correla- 
ion structure) to account for clustering at the subdistrict level. 
e included participants with complete data for all variables in 
he model (complete case analysis). We adjusted by PCV13 vacci- 
ation status, season (month of swab collection), age group, sub- 
istrict type (ger, mixed, apartment), housing type (formal or infor- 
al), maternal education, household income, household crowding 
greater than three people per room), number of children under 
ve years of age, cigarette exposure, household fuel type, and an- 
ibiotic exposure (Supplementary Table 3). These covariates were 
elected a priori using a directed acyclic graph (DAG), informed by 
elevant literature and refined through expert consultation (Sup- 
lementary Figure 1). The linearity assumption was tested using a 
owess plot. To present the results of the above model, we esti- 
ated and graphed the marginal mean VT carriage rate by decile 
f PCV13 coverage, accounting for the balance of the other covari- 
tes across all individuals. Marginal mean VT carriage rate was de- 
ermined using the margins and marginsplot commands in Stata. 
ince PCV13 status was included as a covariate in the adjusted 
odel, we were able to calculate adjusted vaccine effectiveness 
VE) as one minus the odds ratio of PCV13 carriage in vaccinated 
ersus under-vaccinated children multiplied by 100 (Aim 3). 
We conducted an additional analysis exploring an interaction 
etween PCV13 coverage and subdistrict-type since we hypothe- 
ized that children living in ger subdistricts would be at higher risk 
f pneumococcal carriage and higher coverage may be required 
o achieve indirect effects in this setting. We chose to include 
ubdistrict-type as an interaction term rather than individual-level 
ousing type since indirect effects are generated at a community 
ather than individual level. 
To act as a bias indicator, we developed an additional model 
sing overall pneumococcal carriage as the outcome, since most 
tudies indicate that PCV13 does not affect overall pneumococcal 
arriage (due to replacement with non-VTs). 18 , 31 Since hospital- 
ased carriage surveillance among children with pneumonia may 
e affected by prior antibiotic use, we also presented supplemen- 
ary data on the presence of antimicrobial resistance (AMR) genes 
o assess the validity of our findings. 
All analyses were undertaken using Stata 15. 32 The community- 
ontributed command baselinetable was used to construct Table 
. 33 
.6. Sample size 
Sample size calculations were based on Aim 2. As described 
n the published protocol, calculations performed using nQuery 
dvisor + nTerim 4.0 were based on sample size methods for logis- 
ic regression models with a continuous covariate (i.e., PCV13 cov- 
rage) with inflation to account for clustering within subdistricts 
intraclass coefficient of 0.1). 27 We assumed a VT carriage rate of 
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Table 1 
Characteristics of participants tested for pneumococcal carriage by vaccination status ∗ , Ulaanbaatar, Mongolia, November 2015-March 2019 
Under-vaccinated Vaccinated Missing vaccination status Total 
N = 677 N = 509 N = 97 N = 1 283 
Age (months) (N = 1 283) † 15 (6-28) 15 (9-22) 17 (8-26) 15 (7-25) 
Gender (N = 1 283) 
Female 319 (47 • 1%) 217 (42 • 6%) 33 (34 • 0%) 569 (44 • 3%) 
Male 358 (52 • 9%) 292 (57 • 4%) 64 (66 • 0%) 714 (55 • 7%) 
Season ‡ (N = 1 283) 
Warm 332 (49 • 0%) 265 (52 • 1%) 77 (79 • 4%) 674 (52 • 5%) 
Cold 345 (51 • 0%) 244 (47 • 9%) 20 (20 • 6%) 609 (47 • 5%) 
Household income§ (N = 1 206) 
At or below minimum 303 (48 • 3%) 220 (44 • 9%) 36 (40 • 4%) 559 (46 • 4%) 
Above minimum 324 (51 • 7%) 270 (55 • 1%) 53 (59 • 6%) 647 (53 • 6%) 
Maternal education (N = 1 261) 
Tertiary 337 (50 • 7%) 258 (51 • 6%) 46 (47 • 9%) 641 (50 • 8%) 
Secondary school or less 328 (49 • 3%) 242 (48 • 4%) 50 (52 • 1%) 620 (49 • 2%) 
Crowding (N = 1 244) 
< = 3 people per room 356 (54 • 0%) 273 (55 • 4%) 53 (57 • 6%) 682 (54 • 8%) 
> 3 people per room 303 (46 • 0%) 220 (44 • 6%) 39 (42 • 4%) 562 (45 • 2%) 
Other children aged < 5 years in the house (N = 1 245) 
None 431 (65 • 5%) 345 (69 • 3%) 62 (69 • 7%) 838 (67 • 3%) 
At least one child 227 (34 • 5%) 153 (30 • 7%) 27 (30 • 3%) 407 (32 • 7%) 
Smoker in the house (N = 1 263) 304 (45 • 6%) 210 (41 • 9%) 31 (32 • 3%) 545 (43 • 2%) 
Fuel for cooking and heating (N = 1264) 
Gas/electricity 225 (33.7%) 190 (37.9%) 35 (36.5%) 450 (35.6%) 
Wood/coal 442 (66.3%) 311 (62.1%) 61 (63.5%) 814 (64.4%) 
Housing type (N = 1 264) 
Formal 400 (60 • 0%) 325 (64 • 9%) 59 (61 • 5%) 784 (62 • 0%) 
Informal 267 (40 • 0%) 176 (35 • 1%) 37 (38 • 5%) 480 (38 • 0%) 
Subdistrict-type (N = 1 246) 
Ger 298 (45 • 1%) 231 (46 • 8%) 42 (46 • 2%) 571 (45 • 8%) 
Apartment 107 (16 • 2%) 65 (13 • 2%) 14 (15 • 4%) 186 (14 • 9%) 
Mixed 256 (38 • 7%) 198 (40 • 1%) 35 (38 • 5%) 489 (39 • 2%) 
Breastfeeding (N = 1 264) 392 (58 • 9%) 305 (60 • 8%) 41 (42 • 7%) 738 (58 • 4%) 
Received antibiotics in 48 hours prior to admission (N = 1 277) 330 (48 • 9%) 243 (48 • 0%) 44 (45 • 8%) 617 (48 • 3%) 
Received hospital antibiotics prior to swab (N = 1 239) 312 (48 • 0%) 239 (47 • 9%) 41 (45 • 6%) 592 (47 • 8%) 
Pneumococcal carriage (N = 1 283) 337 (49 • 8%) 232 (45 • 6%) 52 (53 • 6%) 621 (48 • 4%) 
Percentage of lytA positive samples, serotype unknown (N = 621) 45 (13 • 4%) 34 (14 • 7%) 10 (19 • 2%) 89 (14 • 3%) 
PCV13 serotype carriage (N = 1 194) 175 (27 • 7%) 73 (15 • 4%) 22 (25 • 3%) 270 (22 • 6%) 
∗Children are considered vaccinated if they have received at least two doses when administered at less than 12 months of age or at least one dose when 
administered at greater than or equal to 12 months of age. 
† See Supplementary Figure 2 for histograms of age distribution by vaccination status 
‡ Cold season refers to the winter months (Nov-March) and warm season refers to non-winter months. 
§The definition of minimum living standard was changed by the Government of Mongolia between in 2017 from 170 0 0 0 ₮ to 241 0 0 0 ₮ per person/per 
month 




































0% at the mean PCV13 coverage level, and a VT carriage rate of 
0% at one standard deviation above the mean. Assuming a signif- 
cance level of 0.05, allowing for adjustment using multiple covari- 
tes with an R 2 of 0.4, 600 under-vaccinated participants would 
rovide 87% power to detect the association between PCV13 cover- 
ge and VT carriage. 
.7. Ethics approvals 
This study was conducted according to the protocols approved 
y the Mongolian National Ethics Committee for Health Research, 
he Royal Children’s Hospital (33177B) and the WHO Regional Of- 
ce for the Western Pacific (WPRO) Ethics Research Committee 
2013.30.LAO.2.EPI). 
.8. Role of the funding source 
This work is supported by the Bill & Melinda Gates Founda- 
ion (grant number OPP1115490) and the Gavi Alliance (contract 
umber PP61690717A2). JC is funded by the Australian Govern- 
ent Research Training Program scholarship. FMR is funded by 
 NHMRC Investigator grant. CS was supported by an Australian 
HMRC Career Development Fellowship (1087957) and a Veski 5 nspiring Women Fellowship. MCRI was supported by the Victo- 
ian Government’s Operational Infrastructure Support Program. The 
unders had no role in study design, data collection and analysis, 
ecision to publish, or preparation of the manuscript. 
. Results 
.1. Participant characteristics 
Between November 2015 and March 2019, we enrolled 6 049 
hildren 2-59 months of age (inclusive) and tested a random sam- 
le of 1 283 participants for pneumococcal carriage (median 32 • 5 
ampled per month, interquartile range 32 • 0-33 • 0 per month). The 
 283 participants were representative of the overall participants 
nrolled, with the exception of season, since enrolment of partic- 
pants with pneumonia greatly increased during the cold season, 
hile monthly random sampling did not change over time (Sup- 
lementary Table 4). 
Among the participants who were under-vaccinated, 81 • 2% 
eceived no doses. Compared with vaccinated children, under- 
accinated children were more likely to carry PCV13 serotypes 
 Table 1 ). The characteristics of participants that were tested for 
neumococcal carriage were consistent over time, although partic- 
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Table 2 
Characteristics of participants tested for pneumococcal carriage by subdistrict type, Ulaanbaatar, Mongolia, November 2015-March 2019 
Ger subdistrict Mixed subdistrict Apartment subdistrict Total 
N = 571 N = 489 N = 186 N = 1246 
Age (months) (N = 1246) 14 (7-24) 18 (10-29) 15 (7-25) 15 (7-25) 
Gender (N = 1246) 
Female 257 (45.0%) 223 (45.6%) 72 (38.7%) 552 (44.3%) 
Male 314 (55.0%) 266 (54.4%) 114 (61.3%) 694 (55.7%) 
District (N = 1246) 
Songinokhairkhan 360 (63.0%) 353 (72.2%) 64 (34.4%) 777 (62.4%) 
Sukhbaatar 211 (37.0%) 136 (27.8%) 122 (65.6%) 469 (37.6%) 
Season ∗ (N = 1246) 
Warm season 294 (51.5%) 247 (50.5%) 109 (58.6%) 650 (52.2%) 
Cold season 277 (48.5%) 242 (49.5%) 77 (41.4%) 596 (47.8%) 
Household income † (N = 1174) 
At or below minimum level 281 (52.3%) 199 (43.2%) 64 (36.4%) 544 (46.3%) 
Above minimum level 256 (47.7%) 262 (56.8%) 112 (63.6%) 630 (53.7%) 
Maternal education (N = 1229) 
Tertiary 246 (43.6%) 230 (47.6%) 152 (83.5%) 628 (51.1%) 
Secondary school or less 318 (56.4%) 253 (52.4%) 30 (16.5%) 601 (48.9%) 
Household crowding (people/room) (N = 1214) 
≤ 3 people per room 267 (47.8%) 261 (54.8%) 140 (77.8%) 668 (55.0%) 
> 3 people per room 291 (52.2%) 215 (45.2%) 40 (22.2%) 546 (45.0%) 
Other children aged < 5 years living in the house (N = 1214) 
None 357 (64.1%) 347 (72.1%) 114 (64.8%) 818 (67.4%) 
At least one child 200 (35.9%) 134 (27.9%) 62 (35.2%) 396 (32.6%) 
Cigarette smoker in the house (N = 1231) 309 (54.7%) 267 (55.2%) 122 (67.0%) 698 (56.7%) 
Fuel for cooking and heating (N = 1232) 
Gas/electricity 115 (20.4%) 161 (33.2%) 161 (88.5%) 437 (35.5%) 
Wood/coal 450 (79.6%) 324 (66.8%) 21 (11.5%) 795 (64.5%) 
Housing type (N = 1232) 
Formal housing 308 (54.5%) 287 (59.2%) 172 (94.5%) 767 (62.3%) 
Informal housing 257 (45.5%) 198 (40.8%) 10 (5.5%) 465 (37.7%) 
Currently breastfeeding (N = 1232) 335 (59.3%) 289 (59.6%) 93 (51.1%) 717 (58.2%) 
Oral antibiotics within 48 hours prior to admission (N = 1240) 264 (46.4%) 240 (49.4%) 91 (49.2%) 595 (48.0%) 
Received hospital antibiotics prior to swab (N = 1209) 280 (50.3%) 225 (47.3%) 74 (42.0%) 579 (47.9%) 
PCV13 vaccination status ‡ (N = 1155) 
Under-vaccinated 298 (56.3%) 256 (56.4%) 107 (62.2%) 661 (57.2%) 
Vaccinated 231 (43.7%) 198 (43.6%) 65 (37.8%) 494 (42.8%) 
Pneumococcal carriage (N = 1246) 287 (50.3%) 252 (51.5%) 64 (34.4%) 603 (48.4%) 
lytA positive samples, serotype unknown§ (N = 434) 52 (18.1%) 29 (11.5%) 7 (10.9%) 88 (14.6%) 
Vaccine-type carriage (N = 1158) 111 (21.4%) 116 (25.2%) 31 (17.3%) 258 (22.3%) 
∗ Cold season refers to the winter months (Nov-March) and warm season refers to non-winter months. 
† The definition of minimum living standard was changed by the Government of Mongolia between in 2017 from 170 0 0 0 ₮ to 241 0 0 0 ₮ per person/per 
month 
‡ Children are considered vaccinated if they have received at least two doses when administered at less than 12 months of age or at least one dose 
when administered at greater than or equal to 12 months of age. 





































pants enrolled from the two districts varied over time (Supple- 
entary Table 5 and Supplementary Figure 3). Pneumococcal risk 
actors, including household crowding and use of wood or coal for 
uel, and pneumococcal carriage were higher among children from 
er and mixed subdistricts than children from apartment subdis- 
ricts ( Table 2 ). The proportion of missing data was less than 10%
or all variables including PCV13 status (7 • 5% missing). 
Out of 1 283 participants, the pneumococcal carriage rate was 
8 • 4% (95% CI 45 • 6-51 • 2) and the majority were serotyped (85 • 7%).
T carriage rate was 22 • 6% (95% CI 20 • 3-25 • 1). Carriage charac-
eristics were similar by vaccinations status, aside from lower VT 
arriage among vaccinated children ( Table 1 ). Rate of AMR genes 
mong lytA positive samples was 89 • 1% and the rate did not vary 
y vaccination status or over time (Supplementary Table 6). 
.2. Pneumococcal carriage over time 
VT carriage declined first among vaccinated participants, fol- 
owed by under-vaccinated participants ( Figure 1 ). There appeared 
o be a slight increase in VT carriage, especially among under- 
accinated participants, at the end of the study period. How- 
ver case numbers were small since there were fewer forward 
onths to include in the rolling five-month intervals. The individ- 6 al serotypes identified are graphed by year in Supplementary Fig- 
re 2. 
.3. PCV13 coverage 
Among children under five years of age, coverage of at least 
wo doses of PCV13 increased to 70 • 2% in Sukhbaatar and 77 • 1%
n Songinokhairkhan by March 2019 ( Figure 2 ). 
.4. Association between PCV13 coverage and indirect effects 
A description of the data available for this analysis are pre- 
ented in Supplementary Table 7. For each increase in percent- 
ge point of PCV13 coverage, the adjusted odds of VT carriage 
ecreased by 1 • 0% (0 • 4-1 • 7% [OR 0 • 990, 95% CI 0 • 983-0 • 996];
 = 0 • 001) ( Table 3 ). As coverage increases from 0% to 100%, the ad-
usted model predicts that PCV13 carriage will decrease from 29 • 1% 
95% CI 22 • 4-35 • 8%) to 13 • 1% (95% CI 8 • 6-17 • 5%) ( Figure 3 ). The ad-
usted PCV13 vaccine effectiveness against VT carriage was 39 • 1% 
95% CI 11 • 4-58 • 1%, p = 0 • 009). As expected, there was no evidence
f an association between PCV13 coverage and overall pneumo- 
occal carriage, the bias indicator, after adjustment ( Table 3 and 
igure 3 ). 
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Figure 1. Monthly adjusted ∗ prevalence of vaccine-type carriage (5-month rolling intervals) among 2–59-month-old participants with pneumonia, by PCV13 status, Ulaan- 
baatar, November 2015-March 2019; black dashed line (—) indicates date of PCV13 introduction 
∗Adjusted by age group 
Figure 2. Monthly 13-valent pneumococcal conjugate vaccine (PCV13) coverage ∗ among children under five years of age by district, Ulaanbaatar, 2016 – 2019 
∗Coverage defined as the number of children who had received at least two doses of PCV13 divided by the total number of children under five years within each district 
7 
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Table 3 
Adjusted ∗ and unadjusted odds ratios of vaccine-type and overall pneumococcal carriage, by percentage increase in district 13-valent pneumococcal conjugate vaccine (PCV13) 
coverage † and individual PCV13 status ‡ , Ulaanbaatar, Mongolia, 2015-2019 
Unadjusted Adjusted ∗
OR (95% CI) p-value OR (95% CI) p-value 
Vaccine-type carriage 
PCV13 coverage † at each participants’ resident district at time of enrolment 0 ·984 (0 ·980-0 ·989) < 0 ·001 0 ·990 (0 ·983-0 ·996) 0 ·001 
Individual PCV13 status ‡ 0 ·494 (0 ·367-0 ·663) < 0 ·001 0 ·609 (0 ·419-0 ·886) 0 ·009 
PCV13 effectiveness (%)§ 50 ·6 (33 ·7-63 ·3) < 0 ·001 39 ·1 (11 ·4-58 ·1) 0 ·009 
Overall pneumococcal carriage 
PCV13 coverage † at each participants’ resident district at time of enrolment 0 ·997 (0 ·992-1 ·001) 0 ·143 0 ·998 (0 ·992-1 ·005) 0 ·575 
Individual PCV13 status ‡ 0 ·859 (0 ·712-1 ·04) 0 ·112 0 ·917 (0 ·749-1 ·124) 0 ·406 
PCV13 effectiveness (%)§ 14 ·1(-0 ·04-28 ·8) 0 ·112 8 ·3 (-12 ·4-25 ·1) 0 ·406 
∗Adjusted by PCV13 vaccination status, season, age group, subdistrict-type, housing type, maternal education, household income, household crowding, number of children 
under five years of age, cigarette exposure, household fuel type, and antibiotic exposure 
† Coverage is defined as percentage of children under five years of age who have received at least two doses of PCV13. 
‡ Odds ratio of carriage among vaccinated compared to under-vaccinated participants, where vaccination is defined as receipt of at least two doses when administered at less 
than 12 months of age or at least one dose when administered at greater than or equal to 12 months of age. 
§PCV13 effectiveness against carriage is calculated as one minus the odds ratio for the association between individual PCV13 status and carriage, multiplied by 100. 
Figure 3. Adjusted ∗ and unadjusted probability of vaccine-type (VT) and overall pneumococcal carriage by level of district 13-valent pneumococcal conjugate vaccine (PCV13) 
coverage † , Ulaanbaatar, Mongolia, 2015-2019; each circle represents data from children enrolled within the same month and district. 
∗Adjusted by vaccination status, season, age group, subdistrict-type, housing-type, maternal education, household income, household crowding, number of children under 
five years of age, cigarette exposure, household fuel type, and antibiotic exposure 






















While a Wald test did not indicate an interaction between cov- 
rage and subdistrict-type (p = 0 • 100), there was a trend towards 
 steeper decline in the odds of VT carriage for each percentage 
oint increase in PCV13 coverage among children from apartment 
ubdistricts (1 • 5% [95% CI -0 • 7-3 • 7%]), followed by mixed housing
ubdistricts (0 • 7% [95% CI -0 • 3-1 • 7) and ger subdistricts (0 • 6% [95%
I -0 • 2-1 • 4%]) ( Figure 4 ) 
. Discussion 
Our study found evidence of indirect effects against VT carriage 
n Mongolia, including among children living in subdistricts com- 
rised of informal (ger) housing, who have a higher burden of risk 8 actors for pneumococcal disease. While coverage only reached 75% 
uring our observation period, our model predicts that as coverage 
eaches 100% among children under five years of age, VT carriage 
ould reduce by 55 • 0% (from 29 • 1% to 13 • 1% carriage rate) through
ndirect effects alone. Our results are consistent with community 
arriage surveys in Ulaanbaatar which found a 51% reduction in 
T carriage in unvaccinated infants aged 5-8 weeks one year after 
CV13 introduction. 20 These reductions in VT carriage are expected 
o translate to reductions in VT disease, since carriage is a prereq- 
isite for disease. 2 
We found that indirect effects against VT carriage started at low 
evels of vaccine coverage, challenging assumptions that high vac- 
ine coverage is required for indirect effects. We recently reported 
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Figure 4. Adjusted ∗ probability of vaccine-type carriage by level of 13-valent pneumococcal conjugate vaccine (PCV13) coverage † and subdistrict-type, Ulaanbaatar, Mongolia, 
2015-2019 
∗Adjusted by vaccination status, season, age group, subdistrict-type, housing-type, maternal education, household income, household crowding, number of children under 
five years of age, cigarette exposure, household fuel type, and antibiotic exposure 
























































imilar associations between vaccine coverage and indirect effects 
gainst VT carriage in Lao Peoples’ Democratic Republic (Lao PDR) 
where we predicted a 36% relative reduction in VT carriage as 
overage increased to 60% despite heterogenous PCV13 coverage. 34 
his relationship has also been demonstrated for pneumococcal 
isease. 35 , 36 
While indirect effects were observed in children living in both 
ormal and informal settlements, there was a trend towards greater 
eductions in VT carriage at lower levels of coverage for children 
iving in apartment subdistricts, compared to children living in ger 
ubdistricts. This may be attributable to the higher rate of VTs 
mong children living in ger subdistricts. 20 Children living in gers 
re at greater risk of pneumococcal infection due to household 
rowding – which contributes to increased exposure to both pneu- 
ococcus and viral co-infection. 37 A lack of sanitation infrastruc- 
ure and use of biomass fuels with resulting indoor air pollution 
ay also contribute an increased risk of pneumococcal carriage. 38 
n alternative explanation is that our analysis, which was based 
n district-level coverage data, may have obscured differences in 
CV coverage at the subdistrict level, with higher coverage result- 
ng in greater reductions in VT carriage in apartment subdistricts. 
owever previous reports indicate there is very little difference 
n vaccination coverage by wealth quintile within urban Ulaan- 
aatar. 8 Future studies designed to specifically study this may pro- 
ide stronger evidence of interactions between PCV coverage and 
ettlement-type. 39 
Our results are consistent with dynamic models suggesting that 
igher rates of PCV coverage are required to effectively interrupt 
erson-to-person transmission in populations with high preva- 
ence and transmission of VTs. 40 Indeed, high vaccination cover- 9 ge among children under five years alone may not be sufficient 
o control VTs in settings with high VT carriage prevalence. Studies 
rom Fiji indicate that following PCV introduction, VT carriage was 
ssociated with physical contact with unvaccinated children 7-14 
ears of age. 41 In these situations, alternative schedules or wider 
atch-up programs may be required to cover age groups acting as 
 reservoir for VTs. 42 
Our results also demonstrate strong direct effects against VT 
arriage for vaccinated children, in-line with previous estimates 
rom other countries. In Lao PDR, which uses a schedule with 
hree infant doses, we reported VE of 38 • 1% against VT carriage 
mong children under five. 34 In Brazil, three doses of PCV10 had 
4% effectiveness against VT carriage among healthy children 7- 
1 months of age. 43 Two PCV13 doses conferred 53% protection 
gainst VT carriage among healthy children aged ≤12 months in 
srael. 26 As expected, our estimates of VE against VT carriage are 
ower compared to effectiveness of PCV13 against VT disease. 44 
A key strength the study method pioneered by Ali et al 45 is the 
ias indicator analysis. Using similar methods, we showed no as- 
ociation between PCV13 coverage and overall pneumococcal car- 
iage, which supports the internal validity of the study. Despite 
onducting this study among children with pneumonia, our re- 
ults are consistent with previous pneumococcal carriage studies 
onducted among healthy children who had not been exposed to 
ntibiotics. Furthermore, rates of VTs and AMR genes among our 
tudy population were similar to a previous community carriage 
urvey of healthy children from Ulaanbaatar. 20 
An important limitation of our study was that estimates of 
accine coverage were based on administrative data. 46 National 
stimates are likely to be reliable in Mongolia, where PCV13 is 



















































































elivered through a well-structured public health care system and 
revious surveys indicate high accuracy of administrative cover- 
ge estimates, based on family health centre records. 17 , 47 The elec- 
ronic immunisation register, which was used as an adjunct to 
arent-held child health cards to determine participant vaccination 
tatus, has previously been demonstrated to have high degree of 
ccuracy when compared to family health centre records. 23 How- 
ver, at a district level, population movement between districts el- 
gible and ineligible for PCV means that the real vaccine coverage 
ay be lower than the documented administrative estimates. This 
uggests that indirect effects may in fact be achievable in Mongolia 
t lower rates of vaccine coverage than we have reported. 
Our definition of under-vaccinated children included those who 
eceived one dose of vaccine under 12 months of age and may 
enefit from some direct protection. 25 , 26 Therefore, our estimates 
f VE may be lower than studies with comparisons against com- 
letely unvaccinated children, while overestimating the relation- 
hip between vaccine coverage and indirect effects. However, 
he effect is likely to be minimal since the majority of under- 
accinated children received no doses (81 • 2%). 
Our findings have important policy implications for Mongolia 
nd other countries in the region. Firstly, the cost-effectiveness of 
he vaccine greatly improves when the indirect effects are present 
nd taken into account, which can help policy makers justify pub- 
ic funding of the vaccine. 48 Secondly, indirect effects are neces- 
ary for the control of VT transmission, which is a prerequisite for 
he use of reduced dose schedules. 7 Our results suggest VT con- 
rol may not be achieved despite high coverage in the short-term 
n Mongolia. Further research is urgently needed to monitor long- 
erm impacts and develop strategies to achieve VT control in high 
arriage settings, which would enable such settings to transition 
o cost-saving reduced dose schedules. We recommend prioritis- 
ng research on understanding the remaining reservoirs for VT in- 
ection post-PCV and evaluating alternative vaccination strategies, 
uch as additional booster doses or wider catch-up programs cov- 
ring older children. While our study focuses on the direct and in- 
irect effects of PCV, further research is also required to under- 
tand the degree to which corresponding increases in non-vaccine 
ype pneumococcal carriage (also known as serotype replacement) 
ay impact on the public health gains resulting from PCVs. 49 , 50 
ur results provide insight into the conditions necessary to gener- 
te strong indirect effects in Mongolia and have important impli- 
ations for other countries in the region, many of which have yet 
o introduce PCV into routine childhood immunisation schedules. 
. Contributors 
FMR conceived the idea and designed the study. TM, SLV, CVM, 
N, EKM, JC and FMR supported the development of country- 
pecific protocols. TM led study implementation with support from 
LV, CVM, PB, MU, BS, DO, DL, DN, UC, EM, GD, EJ and AS. CS de-
ised the microbiological approach and laboratory protocols with 
MD and JH. Laboratory analysis was completed by CLP and MLN. 
C, CN and FMR devised the analysis plan. JC completed the anal- 
sis and drafted the manuscript. All authors provided feedback to 
he draft manuscript and have approved the final version. 
eclaration of Competing Interest 
KM, CDN ED, CS, TM and CVM are investigators on a separate 
tudy that received grant funding from Pfizer. JH is Co-founder and 
hareholder of BUGS Bioscience Ltd., a not-for-profit spin-out com- 
any of St George’s, University of London. KF was on the National 
oundation for Infectious Diseases Planning Committee for Vacci- 
ology Conference. 10 cknowledgements 
We would like to thank the Ministry of Health of Mongolia 
nd the staff at the National Centre for Communicable Diseases 
n Mongolia, particularly the Expanded Programmes of Immuniza- 
ions team, for their support and advice. We also thank research 
nd administrative staff at the Murdoch Children’s Research Insti- 
ute. Finally, we thank the families who participated in this study. 
ata-sharing statement 
Monthly district-level PCV coverage data are available in sup- 
lementary materials. De-identified participant data, including 
neumococcal carriage data, are available on request, subject to 
thical approval. Requests should be directed Professor Fiona Rus- 
ell (fmruss@unimelb.edu.au). 
upplementary materials 
Supplementary material associated with this article can be 
ound, in the online version, at doi: 10.1016/j.lanwpc.2021.100231 . 
eferences 
[1] Wahl B , O’Brien KL , Greenbaum A , et al. Burden of Streptococcus pneumo-
niae and Haemophilus influenzae type b disease in children in the era of con- 
jugate vaccines: global, regional, and national estimates for 20 0 0–15. Lancet 
Glob Health 2018;6:e744–57 . 
[2] Simell B , Auranen K , Käyhty H , et al. The fundamental link between pneumo-
coccal carriage and disease. Expert Rev Vaccines 2012;11:841–55 . 
[3] Pilishvili T , Zell ER , Farley MM , et al. Risk factors for invasive pneumo-
coccal disease in children in the era of conjugate vaccine use. Pediatrics 
2010;126:e9–17 . 
[4] Mullholland K , Weber MW . Pneumonia in Children: Epidemiology, Prevention 
and Treatment. Pinter & Martin Limited; 2016 . 
[5] Feikin DR , Kagucia EW , Loo JD , et al. Serotype-specific changes in invasive
pneumococcal disease after pneumococcal conjugate vaccine introduction: a 
pooled analysis of multiple surveillance sites. PLOS Med 2013;10:e1001517 . 
[6] Davis SM , Deloria-Knoll M , Kassa HT , O’Brien KL . Impact of pneumococ-
cal conjugate vaccines on nasopharyngeal carriage and invasive disease 
among unvaccinated people: Review of evidence on indirect effects. Vaccine 
2013;32:133–45 . 
[7] Flasche S , Van Hoek AJ , Goldblatt D , et al. The Potential for Reducing the Num-
ber of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immu- 
nity in High-Income Countries. PLOS Med 2015;12:e1001839 . 
[8] Center for Health Development. Health Indicators 2016 - Mongolia. Ulaan- 
baatar, Mongolia https://untobaccocontrol.org/impldb/wp-content/uploads/ 
mongolia _ 2018 _ annex-1 _ health _ indicator _ 2016.pdf (accessed Jan 19, 2021). 
[9] von Mollendorf C , La Vincente S , Ulziibayar M , et al. Epidemiology of pneumo-
nia in the pre-pneumococcal conjugate vaccine era in children 2-59 months of 
age, in Ulaanbaatar, Mongolia, 2015-2016. PLOS One 2019;14:e0222423 . 
[10] Jadambaa A, Spickett J, Badrakh B, Norman RE. The Impact of the Environment 
on Health in Mongolia: A Systematic Review. Asia Pac J Public Health 2014 
published online Aug 10. doi: 10.1177/1010539514545648 . 
[11] National Statistics Office of Mongolia. 2015 Population and Housing By-Census 
of Mongolia: National Report. 2016 https://www.en.nso.mn:443/content/166 
(accessed Sept 27, 2020). 
[12] Fan P , Chen J , John R . Urbanization and environmental change during the eco-
nomic transition on the Mongolian Plateau: Hohhot and Ulaanbaatar. Environ 
Res 2016;144:96–112 . 
[13] Park H , Fan P , John R , Ouyang Z , Chen J . Spatiotemporal changes of infor-
mal settlements: Ger districts in Ulaanbaatar, Mongolia. Landsc Urban Plan 
2019;191:103630 . 
[14] von Mollendorf C , Cohen C , de Gouveia L , et al. Risk Factors for Inva-
sive Pneumococcal Disease Among Children Less Than 5 Years of Age in a 
High HIV Prevalence Setting, South Africa, 2010 to 2012. Pediatr Infect Dis J 
2015;34:27–34 . 
[15] Lancet T . Urbanisation, inequality, and health in Asia and the Pacific. The 
Lancet 2017;389:1370 . 
[16] International Vaccine Access Centre. ViewHub. https://view-hub.org/ (accessed 
Jan 11, 2021). 
[17] La Vincente SF, Von Mollendorf C, Ulziibayar M, et al. Evaluation of a phased 
pneumococcal conjugate vaccine introduction in Mongolia using enhanced 
pneumonia surveillance and community carriage surveys: A study protocol 
for a prospective observational study and lessons learned. BMC Public Health 
2019;19. doi: 10.1186/s12889-019- 6639- y . 
[18] Chan J , Nguyen CD , Lai JYR , et al. Determining the pneumococcal conju-
gate vaccine coverage required for indirect protection against vaccine-type 
pneumococcal carriage in low and middle-income countries: a protocol for a 
prospective observational study. BMJ Open 2018;8:e021512 . 































[19] World Health Organization. Pneumococcus: Vaccine Preventable Diseases 
Surveillance Standards. 2018 https://www.who.int/publications/m/item/ 
vaccine-preventable-diseases-surveillance-standards-pneumococcus (accessed 
Jan 5, 2021). 
20] von Mollendorf C , Dunne EM , La Vincente S , et al. Pneumococcal carriage in
children in Ulaanbaatar, Mongolia before and one year after the introduction 
of the 13-valent pneumococcal conjugate vaccine. Vaccine 2019;37:4068–75 . 
[21] Ali M , Emch M , von Seidlein L , et al. Herd immunity conferred by killed oral
cholera vaccines in Bangladesh: a reanalysis. The Lancet 2005;366:44–9 . 
22] World Health Organization and UNICEF. Mongolia: WHO and UNICEF esti- 
mates of immunization coverage: 2019 revision. 2020 http://158.232.12.119/ 
immunization/monitoring _ surveillance/data/mng.pdf (accessed Oct 25, 2020). 
23] Chan J , Mungun T , Dorj N , et al. High agreement between the new Mongolian
electronic immunization register and written immunization records: a health 
centre based audit. West Pac Surveill Response J WPSAR 2017;8:5–10 . 
24] Satzke C , Turner P , Virolainen-Julkunen A , et al. Standard method for detecting
upper respiratory carriage of Streptococcus pneumoniae: updated recommen- 
dations from the World Health Organization Pneumococcal Carriage Working 
Group. Vaccine 2013;32:165–79 . 
25] Scott P , Rutjes AWS , Bermetz L , et al. Comparing pneumococcal conjugate vac-
cine schedules based on 3 and 2 primary doses: systematic review and meta–
analysis. Vaccine 2011;29:9711–21 . 
26] Lewnard JA , Givon-Lavi N , Dagan R . Dose-specific Effectiveness of 7- and
13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Strep- 
tococcus pneumoniae Colonization in Children. Clin Infect Dis Off Publ Infect 
Dis Soc Am 2020;71:e289–300 . 
27] Satzke C, Dunne EM, Choummanivong M, et al. Pneumococcal carriage in 
vaccine-eligible children and unvaccinated infants in Lao PDR two years fol- 
lowing the introduction of the 13-valent pneumococcal conjugate vaccine. 
2018. DOI:10.1016/j.vaccine.2018.10.077. 
28] Newton R, Hinds J, Wernisch L. Empirical Bayesian models for analysing 
molecular serotyping microarrays. BMC Bioinformatics 2011;12. doi: 10.1186/ 
1471-2105-12-88 . 
29] Satzke C , Dunne EM , Porter BD , Klugman KP , Mulholland EK . The PneuCar-
riage Project: A Multi-Centre Comparative Study to Identify the Best Serotyp- 
ing Methods for Examining Pneumococcal Carriage in Vaccine Evaluation Stud- 
ies. PLOS Med 2015;12:e1001903 . 
30] Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age Stan- 
dardization of Rates: A new WHO Standard. World Health Organization. 
[31] Deen J , Ali M , Sack D . Methods to Assess the Impact of Mass Oral Cholera
Vaccination Campaigns under Real Field Conditions. PLOS One 2014;9:e88139 . 
32] StataCorp. Stata Statistical Software: Release 15. 2019. 
33] Baselinetable Donath S . A command for creating oneand two-way tables of 
summary statistics. Stata J 2018;18:327–44 . 
34] Chan J , Lai JY , von Mollendorf C , et al. Determining the pneumococcal con-
jugate vaccine coverage required for indirect protection within Asia and the 
Pacific: a prospective observational study. Lancet Glob Health 2019;7:S15 . 11 35] Shiri T , Datta S , Madan J , et al. Indirect effects of childhood pneumococcal con-
jugate vaccination on invasive pneumococcal disease: a systematic review and 
meta-analysis. Lancet Glob Health 2017;5:e51–9 . 
36] Chan J , Gidding HF , Blyth C , et al. Determining the vaccination coverage re-
quired for indirect protection against invasive pneumococcal disease, Australia. 
In: National Immunisation Conference. Adelaide; 2018 . 
37] Collins DA , Hoskins A , Snelling T , et al. Predictors of pneumococcal carriage
and the effect of the 13-valent pneumococcal conjugate vaccination in the 
Western Australian Aboriginal population. Pneumonia Nathan Qld 2017;9:14 . 
38] Dunne EM , Choummanivong M , Neal EFG , et al. Factors associated with pneu-
mococcal carriage and density in infants and young children in Laos PDR. PLOS 
One 2019;14:e0224392 . 
39] Brookes ST , Whitely E , Egger M , Smith GD , Mulheran PA , Peters TJ . Subgroup
analyses in randomized trials: risks of subgroup-specific analyses;: power and 
sample size for the interaction test. J Clin Epidemiol 2004;57:229–36 . 
40] Lourenço J , Obolski U , Swarthout TD , et al. Determinants of high residual
post-PCV13 pneumococcal vaccine-type carriage in Blantyre, Malawi: a mod- 
elling study. BMC Med 2019;17:219 . 
[41] Neal EFG , Flasche S , Nguyen CD , et al. Associations between ethnicity, social
contact, and pneumococcal carriage three years post-PCV10 in Fiji. Vaccine 
2020;38:202–11 . 
42] Swarthout TD , Fronterre C , Lourenço J , et al. High residual carriage of vac- 
cine-serotype Streptococcus pneumoniae after introduction of pneumococcal 
conjugate vaccine in Malawi. Nat Commun 2020;11:2222 . 
43] Andrade AL , Ternes YM , Vieira MA , et al. Direct effect of 10-valent conjugate
pneumococcal vaccination on pneumococcal carriage in children Brazil. PLOS 
One 2014;9:e98128 . 
44] Berman-Rosa M, O’Donnell S, Barker M, Quach C. Efficacy and Effectiveness 
of the PCV-10 and PCV-13 Vaccines Against Invasive Pneumococcal Disease. 
Pediatrics 2020;145. doi: 10.1542/peds.2019-0377 . 
45] Ali M , Emch M , von Seidlein L , et al. Herd immunity conferred by killed oral
cholera vaccines in Bangladesh: a reanalysis. The Lancet 2005;366:44–9 . 
46] Cutts FT , Claquin P , Danovaro-Holliday MC , DA Rhoda . Monitoring vaccination
coverage: Defining the role of surveys. Vaccine 2016;34:4103–9 . 
[47] Immunization country profiles: Mongolia. UNICEF DATA. 2018; 
published online July 17. https://data.unicef.org/resources/ 
immunization- country- profiles/ (accessed Nov 24, 2020). 
48] Holubar M , Stavroulakis MC , Maldonado Y , Ioannidis JPA , Contopoulos-Ioan- 
nidis D . Impact of vaccine herd-protection effects in cost-effectiveness analy- 
ses of childhood vaccinations. A quantitative comparative analysis. PLOS One 
2017;12:e0172414 . 
49] Chan J , Nguyen CD , Dunne EM , et al. Using pneumococcal carriage stud-
ies to monitor vaccine impact in low- and middle-income countries. Vaccine 
2019;37:6299–309 . 
50] Lewnard JA , Hanage WP . Making sense of differences in pneumococcal 
serotype replacement. Lancet Infect Dis 2019;19:e213–20 . 
